Inclusion Criteria:

- Have a histological or cytological diagnosis of malignant solid neoplasm requiring
systemic chemotherapy.

- Age ≥18 years.

- ECOG performance status 0-1.

- Adequate organ function.

- Adequate hematological function.

- Have the ability to understand the requirements of the study, provide written
informed consent, and comply with the study protocol procedures.

- Consent to collection of previously obtained, archival biopsy or surgical specimens
of the currently treated malignancy when available.

Exclusion Criteria:

- Significant cardiac disease.

- Eye trauma or disease.

- Ocular surgery or blunt force trauma to the eye requiring treatment within 3 months
prior to first dose of HGS1036.

- Presence or history of ≥ Grade 2 hemoptysis within 2 weeks of the first dose of
HGS1036.

- Major surgery within 4 weeks of the first dose of HGS1036.

- Prior organ or allogeneic stem cell transplant.

- Non-healing or chronic wounds.

- Receipt of any anti-cancer therapy within 4 weeks prior to first dose of HGS1036.

- Receipt of any biological therapy (such as monoclonal antibodies) within 6 weeks of
the first dose of HGS1036.

- Active CNS involvement by primary or metastatic tumor.

- Documented active infection requiring the use of systemic antibiotics.

- Pregnancy or lactation.

- Known HIV-positive serology, AIDS, or an AIDS-related illness.

- Conditions likely to increase the potential for abdominal perforation or fistula
formation.